---
source:
  family: "GUIDANCE"
  instrument: "FDA Guidance"
  title: "Policy On Maximum Timer Interval and Exposure Schedule For Sunlamp Products"
  docket: "FDA-2020-D-0957"
  path: "522_Policy_On_Maximum_Timer_Interval_and_Exposure_Schedule_For_Sunlamp_Products.pdf"
  pages: 6
  converted: 2026-02-27
  method: pdftotext
---

DEPARTMENT OF HEALTH & H U M A N SERVICES

Public Health Service

= .

#16 2 1 (ge6
TO: ALL MANUFACTURERS,
SUNLAMP PRODUCTS.

Food and Drug Adrnmistrat~on
8 7 5 7 Georgia Avenue
Sdver Sprmg MD 209 10

IMPORTERS AND P O T E N T I A L MANUFACTURERS O F

S U B J E C T : P O L I C Y ON MAXIMUM T I M E R INTERVAL AND EXPOSURE SCHEDULE F O R
SUNLAMP PRODUCTS.
BACKGROUND:

The amended performance s t a n d a r d f o r sunlamp products ( 2 1 CFR 1040.29) was
p u b l i s h e d i n t h e September 6, 1985 i s s u e of t h e Federal R e g i s t e r and w i l l
become e f f e c t i v e September 8 , 1986. Any sunlamp product manufactured on o r
a f t e r t h a t d a t e must comply w i t h t h e amended standard.
The t e n ( 1 0 ) minute maximum t i m e r i n t e r v a l requirement was removed
from t h e o r i g i n a l performance s t a n d a r d s i n c e t h e r e a r e newer sunlamp
products on t h e market f o r which t e n (10) minutes is not a p p r o p r i a t e .
The maximum timer i n t e r v a l now depends on t h e i n t e n s i t y and s p e c t r a l
d i s t r i b u t i o n of u l t r a v i o l e t (W)r a d i a t i o n emission of each i n d i v i d u a l
model of sunlamp product and must n o t exceed t h e maximum recommended
exposure time provided on t h e r e q u i r e d product warning l a b e l . T h e r e f o r e ,
sunlamp product manufacturers must develop a n exposure schedule and
e s t a b l i s h t h e maximum recommended exposure tlme (and t h e r e f o r e t h e
maximum t i m e r i n t e r v a l ) based on t h e c h a r a c t e r i s t i c s of t h e i r p a r t i c u l a r
products.
The i n t e n d e d purposes of a sunlamp product t i m e r a r e t o p r o v i d e
f o r r e l i a b l e c o n t r o l of exposures and t o l i m i t a c u t e (and d e l a y e d ) damage
from u n i n t e n t i o n a l l y l o n g exposures. However, t h e maximum timer s e t t i n g ;
s h o u l d a l s o a l l o w f o r s e l e c t i o n o f exposure t i m e s needed t o b u i l d up and
m a i n t a i n a t a n . The maxlmurn t i m e r i n t e r v a l i s i n no way t o be c o n s i d e r e d
a s a s a f e l i m i t ; a l l u l t r a v i o l e t r a d i a t i o n i s p o t e n t i a l l y hazardous.
The s t a n d a r d r e q u i r e s t h e manufacturer t o provide a n exposure s c h e d u l e
i n t h e product warning l a b e l . The purpose o f t h e exposure s c h e d u l e
i s t o a l l o w a person t o g r a d u a l l y build-up s k i n pigmentation and t o
m a i n t a i n a t a n w h i l e c o n t r o l l i n g t h e r i s k of a c u t e i n j u r y and delayed
a d v e r s e e f f e c t s . S i n c e t h e W r a d i a t i o n dose t h a t causes a b a r e l y
d i s c e r n i b l e pink c o l o r a t i o n (minimal erythema1 dose o r MED) i s n o t t h e same
f o r d i f f e r e n t s k i n t y p e s , t h e exposure s c h e d u l e f o r f i r s t time u s e r s w i l l
depend on t h e s k i n t y p e of t h e u s e r . Furthermore, suberythemogenic doses
of W r a d i a t i o n r e c e i v e d at 24 h o u r s i n t e r v a l s i n i t i a l l y l e a d t o lowering;
of t h e erythema and t a n n i n g t h r e s h o l d s . T h e r e f o r e , t h e exposure s c h e d u l e
and maximum recommended exposure t i m e should be c o n s t r a i n e d by t h e
p o t e n t i a l f o r erythema a s w e l l as t h e q u a n t i t y of r a d i a t i o n n e c e s s a r y t o
a c h i e v e and m a i n t a i n a t a n .
POLICY :
The C e n t e r f o r Devices and R a d i o l o g i c a l H e a l t h (CDRH) w i l l u s e t h e
f o l l o w i n g c r i t e r i a t o e v a l u a t e t h e adequacy of t h e exposure s c h e d u l e and
t h e recommended maximum exposure t i m e (and t h e r e f o r e t h e maximum timer
interval):

Page 2
1) The maximum recommended exposure time (and maximum timer
interval) must not exceed a value which will result in an exposure
of four (4) times the minimal erythema dose (MED) for untanned
Type I1 skin (always burns, then tans slightly). This is based on
the CDRH Erythema Action Spectrum [proposed action spectrum of
Commission Internationale de L'Eclairage (CIE) modified by CDRHI.
See Appendix A for the action spectrum and weighting factors and
equations needed to derive it.

The formula for determining the recommended maximum exposure
time,"T " in seconds is :
e
Te = 6 2 4 5 1 ~ ~ where Standard MED = 1565lM2 at 296nm
vi = weighting factor
CViRi
Ri = irradiance in W/M2

.

2) The recommended maximum exposure time must not exceed a value
which will result in an exposure of four (4) times the minimal
melanogenic dose (MMD) for untanned Type I1 skin. This is
based on the melanogenic action spectrum developed by Parrish
et a1 (1982). See Appendix B for this action spectrum.
The formula for determining the recommended maximum exposure time,
" T ~ "in seconds is :
where standard MMD = 459J/M2 at 296nm
J~ = weighting factor
tRi = irradiance in W/M2

3) The recommended exposure schedule should provide for exposures
of no more than 0.75 MED three times the first week, gradually
increasing the exposure the following weeks until maximum tanning
has occurred (approximate,lyfour weeks total) and then provide for
maintenance of a tan by biweekly or weekly exposures of up to
four(4) MEDs or four(4) MMDs, whichever is less.
CDRB believes that the above criteria balances the need to limit acute (and
delayed) damages from unintentionally long exposure and the need to provide
for single exposure durations adequate to achieve and maintain a tan.

Walter E. Gundaker, Director
Office of Compliance
Center for De&es
and
Radiological Health
Appendices

Appendix A
(page 1)

L
n

WEIGHTING

FACTORS

FOR

ERYTHEMA,

Wavelength (nm)

t

The . .
equations
.
. describing the curve are:

Vf

Appendix A

[DATA]GIELYTLE
ERYTHEMA. Vi
CIE ACTION SPECTRUM MODIFIED BY LYTLE (CDRH) NORMALIZED TO 1 AT

READING
1
1
1
1

1
1
1

I
1
1
1
1
1

1

I
1
1
1
1

I
1

I
I
1

1
1
1
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
.7691

5916
.4U

+ WAVELENGTH (nm)
The MMD as function of wavelength has bean interpolated
(using log MMD) fromrthe action spectrum tor melanogenesis
of type 11 skin (~arrishet a1 1982)

Appendix B
(page 2)

TYPE I1

SKIN

1982


